Furthermore, we investigated therapeutic efficacy in vivo in immune-competent mouse models of pancreatic cancer and the ability of AZD1390 and radiation to sensitize both primary and unirradiated contralateral tumors to PD-L1 immunotherapy. The gene discussed is CD274; the disease is pancreatic neoplasm.